Changing utilization of Stavudine (d4T) in HIV‐positive people in 2006–2013 in the EuroSIDA study

Podlekareva, Daria; Grint, Daniel; Karpov, Igor; Vassilenko, Anna; Rakmanova, A; Kamal, Mehnaz; Chentsova, N; Кравченко, Е. Н.; Zeltiņa, Indra; Losso, Marcelo; Parczewski, Miłosz; Lundgren, JD; Mocroft, Amanda; Kirk, Ole; Kundro, M.; Vetter, N; Zangerle, Robert; Mitsura, V. M.; Суетнов, О. Н.; Clumeck, Nathan; Wit, S. De; Delforge, Marc; Florence, Éric; Vandekerckhove, Linos; Hadziosmanovic, Vesnadarjan; Kostov, Kosta; Begovać, Josip; Machala, Ladislav; Jilich, David; Sedláček, Dalibor; Nielsen, Jens; Kronborg, Gitte; Benfield, Thomas; Larsen, M.; Gerstoft, Jan; Katzenstein, Terese L.; Hansen, Alastair; Skinhøj, Peter; Pedersen, Court; Østergaard, Lars; Dragsted, Ulrik Bak; Nielsen, Lise Nikolic; Zilmer, Kai; Smidt, Smidt Jelena; Ristola, Matti; Katlama, Christine; Viard, Jean‐Paul; Girard, Pierre Marie; Vanhems, Philippe; Pradier, Christian; Dabis, François; Néau, Didier; Duvivier, Claudine; Rockstroh, Juergen; Schmidt, [No Value]; Lunzen, Jan van; Degen, Olaf; Stellbrink, H. J.; Bickel, Markus; Goethe, John W.; Bogner, J. R.; Fätkenheuer, Gerd; Kosmidis, J.; Gargalianos, Panagiotis; Xylomenos, G.; Perdios, J.; Sambatakou, H; Bánhegyi, Dénes; Gottfreðsson, Magnús; Mulcahy, Fiona; Yust, Israel; Turner, Dan; Burke, Michael; Pollack, Shimon; Hassoun, Gamal; Elinav, Hila; Haouzi, M.; Monforte, Antonella d’Arminio; Esposito, Roberto; Mazeu, I.; Mussini, Cristina; Arici, Claudio; Pristerà, Raffaele; Mazzotta, Francesco; Gabbuti, Andrea; Vullo, Vincenzo; Lichtner, Miriam; Chirianni, Antonio; Montesarchio, E.; Gargiulo, Miriam; D’Offizi, Gianpiero; Taibi, Chiara; Antinori, Andrea; Lazzarin, Adriano; Castagna, Antonella; Gianotti, Nicola; Galli, Massimo; Ridolfo, Anna Lisa; Rozentāle, Baiba; Chaplinskas, Saulius; Staub, Thérèse; Hemmer, R; Reiss, Peter; Ormaasen, Vidar; Mæland, A; Bruun, Johan N.; Knysz, Brygida; Gąsiorowski, Jacek; Horban, Andrzéj; Bąkowska, Elżbieta; Grzeszczuk, Anna; Flisiak, Robert; Boron-Kaczmarska, Boron-Kaczmarska A.; Pynka, M; Beniowski, Marek; Mularska, E.; H, Trocha; Jabłonowska, Elżbieta; Małolepsza, Ewa; Wójcik, Kamila; Doroana, Manuela; Caldeira, L.; Maltêz, Fernando; Duiculescu, Dan; Rakhmanova, Aza; Buzunova, S; Khromova, Irina; Kuzovatova, Elena; Jevtović, Djordje; Mokrás, M; Staneková, Danica; Tomažič, Janez; González-Lahoz, Juan; Soriano, Vincent; Labarga, Pablo; Moreno, Santiago; Rodríguez, José Manuel ́Ramírez; Clotet, Bonaventura; A, Jou; Paredes, Roger; Tural, Cristina; Puig, Jordi; Bravo, Isabel; Gatell, Josep M.; Miró, José M.; Domingo, Peré; Gutierrez, M.; Mateo, Gràcia; Sambeat, Ma Antònia; Medrano, José; Blaxhult, Anders; Flamholc, Leo; Thalme, Anders; Sönnerborg, Anders; Ledergerber, Bruno; Weber, Rainer; Francioli, P.; Cavassini, Matthias; Hirschel, Bernard; Boffi, E; Furrer, Hansjakob; Battegay, Manuel; Elzi, Luigia; Vernazza, Pietro; Фролов, В М; Kutsyna, Galyna A; Servitskiy, S.; Kuznetsova, Anastasiia; Kyselyova, Galina; Gazzard, Brian; Johnson, AM; Simons, Erica; Phillips, Andrew; Ma, Jun; Orkin, Chloe; Weber, Jonathan; Scullard, George; Fisher, Martin; Leen, Clifford

doi:10.1111/hiv.12254

Cited by 11 publications

(9 citation statements)

References 29 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Characteristics A total of 45 544 individuals were followed in D:A:D since 1 February 2004 and were included in the analysis; these individuals were predominantly white (49.6%), men (73.5%) and had acquired HIV through sex between men, MSM (44.5%) ( Table 1). The median age was 40 [interquartile range (IQR) [34][35][36][37][38][39][40][41][42][43][44][45][46] years at baseline and the median CD4 þ cell count was 434 (IQR 282-621) cells/ml. During a median follow-up of years, a total of 319 ESLD/HCC events occurred (incidence rate 1.01/1000 PYFU, 95% confidence interval 0.90-1.12) of which 209 were ESLD and 110 HCC events.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons

Ryom

Lundgren

Wit

et al. 2016

Aids

View full text Add to dashboard Cite

Cumulative use of d4T, ddI, TDF and APV were independently associated with increased ESLD/HCC rates, and intensified monitoring of liver function should hence be considered among all individuals exposed for longer time periods. The use of d-drugs should furthermore be avoided, where there are alternatives available, and focus should be put on those with longer-term d-drugs exposure who remain at increased ESLD/HCC risk. The unexpected, and viral hepatitis-independent, TDF association calls for further investigations.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In 2010, the WHO launched an initiative aiming to reduce the use of d4T. However, many individuals in resource-limited settings continue to use d-drugs because of their widespread availability and low cost; as such, an estimated 1.1 million individuals still initiated a d4T-based first-line antiretroviral regimen in 2011 [35,36].…”

Section: Introductionmentioning

confidence: 99%

Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons

Ryom

Lundgren

Wit

et al. 2016

Aids

View full text Add to dashboard Cite

show abstract

“…Monitoring the usage and efficacy of ART is central to EuroSIDA's work, alongside surveillance of long-term adverse events [19]. EuroSIDA started to collect data on adverse events in 1998 and information on non-AIDS events have been routinely collected since 2001.…”

Section: Uptake Efficacy Of and Adverse Events To Artmentioning

confidence: 99%

The EuroSIDA study: 25 years of scientific achievements

et al. 2019

Self Cite

View full text Add to dashboard Cite

Go to publication entry in University of Southern Denmark's Research PortalTerms of use This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:• You may download this work for personal use only.• You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying this open access version If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.

show abstract

“…Early HIV diagnosis and treatment are pivotal to maximizing individual and public health benefits of antiretroviral treatment (ART) [ 1 , 2 ]. Despite increased focus on testing and linkage to care in recent years [ 3 ], across Europe, an estimated 40–60% of people do not present for HIV care until their CD4 cell count has decreased below 350 cells/mm3 or they have experienced an AIDS defining disease [ 4 – 6 ]. These late presenters [ 7 ] suffer individual health consequences in terms of high morbidity and mortality, especially during the first year after testing HIV-positive [ 8 – 10 ].…”

Section: Introductionmentioning

confidence: 99%

Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010–2016

Lacombe¹,

Groups²,

Cohere³

2020

BMC Infect Dis

View full text Add to dashboard Cite

Background Late presentation (LP), defined as a CD4 count < 350/mm3 or an AIDS-event at HIV-diagnosis, remains a significant problem across Europe. Linking cohort and surveillance data, we assessed the country-specific burden of LP during 2010–2016 and the occurrence of new AIDS events or deaths within 12 months of HIV-diagnosis believed to be attributable to LP. Methods Country-specific percentages of LP and AIDS-events/death rates (assessed with Poisson regression) observed in The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) and EuroSIDA cohorts, were applied to new HIV-diagnoses reported to the European Centre for Disease Prevention and Control. The estimated number of LP in the whole population was then calculated, as was the number of excess AIDS-events/deaths in the first 12 months following HIV-diagnosis assumed to be attributable to LP (difference in estimated events between LP and non-LP). Results Thirty-nine thousand two hundred four persons were included from the COHERE and EuroSIDA cohorts, of whom 18,967 (48.4%; 95% Confidence Interval [CI] 47.9–48.9) were classified as LP, ranging from 36.9% in Estonia (95%CI 25.2–48.7) and Ukraine (95%CI 30.0–43.8) to 64.2% in Poland (95%CI 57.2–71.3). We estimated a total of > 320,000 LP and 12,050 new AIDS-events/deaths attributable to LP during 2010–2016, with the highest estimated numbers of LP and excess AIDS-events/deaths in Eastern Europe. Country-level estimates of excess events ranged from 17 AIDS-events/deaths (95%CI 0–533) in Denmark to 10,357 (95%CI 7768-147,448) in Russia. Conclusions Across countries in Europe, the burden of LP was high, with the highest estimated number of LP and excess AIDS-events/deaths being in Eastern Europe. Effective strategies are needed to reduce LP and the attributable morbidity and mortality that could be potentially avoided.

show abstract

Changing utilization of Stavudine (d4T) in HIV‐positive people in 2006–2013 in the EuroSIDA study

Cited by 11 publications

References 29 publications

Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons

Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons

The EuroSIDA study: 25 years of scientific achievements

Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010–2016

Contact Info

Product

Resources

About